RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy

RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor

RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents

RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies

RepliCel Adds Independent Director

RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies

RepliCel Announces Record Year in Patents Granted

RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)

RepliCel Closes Second Tranche of Strategic Investment Commitment

RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership